Wegovy to be listed on PBS: A Step Towards Affordable Weight Loss and Diabetes Management
The Pharmaceutical Benefits Advisory Committee (PBAC) has made a significant recommendation that will impact the lives of Australians living with obesity and cardiovascular disease. Wegovy, a medication containing semaglutide, has been endorsed for subsidization through the Pharmaceutical Benefits Scheme (PBS), making it more accessible and affordable for adults with established cardiovascular disease and obesity.
This decision comes as a welcome news for Diabetes Australia's Group CEO, Justine Cain, who emphasizes the importance of supporting individuals in their weight loss journey as a crucial aspect of preventing type 2 diabetes. With type 2 diabetes affecting over 1.3 million Australians and putting another 2 million at risk, the focus on affordable weight loss medications is a vital step towards better health outcomes.
The recommendation highlights a specific criterion for eligibility: adults with established cardiovascular disease (eCVD) who have already experienced a cardiovascular event such as a heart attack or stroke, or those with symptomatic peripheral arterial disease. This targeted approach ensures that the medication is prescribed to those who stand to benefit the most.
Diabetes Australia, along with the Diabetes Alliance, a collective of diabetes-related organizations, advocated for the importance of access to GLP-1 RA medicines like semaglutide in the treatment of obesity. They emphasized the increased risk of chronic conditions, including type 2 diabetes and heart disease, associated with obesity. By making Wegovy more affordable, the government is taking a proactive approach to managing obesity and reducing the rates of these chronic conditions.
Justine Cain expressed her enthusiasm for the positive reception of the sector's advice, viewing it as a significant step in the ongoing efforts to manage obesity and reduce the prevalence of chronic conditions in Australia. This development not only benefits individuals struggling with weight management but also contributes to the broader goal of improving public health and reducing the burden of diabetes in the country.
